Avalo Therapeutics, Inc.
$14.66
▲
6.35%
2026-04-21 05:30:01
www.avalotx.com
NCM: AVTX
Explore Avalo Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$334.08 M
Current Price
$14.66
52W High / Low
$20.72 / $3.39
Stock P/E
—
Book Value
$4.49
Dividend Yield
—
ROCE
-70.45%
ROE
-72.44%
Face Value
—
EPS
$-5.84
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
33
Beta
0.94
Debt / Equity
0.51
Current Ratio
8.14
Quick Ratio
8.14
Forward P/E
-4.5
Price / Sales
5,276.11
Enterprise Value
$213.38 M
EV / EBITDA
-2.94
EV / Revenue
3,616.63
Rating
Strong Buy
Target Price
$40.09
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Janux Therapeutics, Inc. | $15.87 | — | $962.36 M | — | -16.15% | -11.48% | $35.34 / $12.12 | $15.85 |
| 2. | Psyence Biomedical Ltd. | $11.3 | 30.05 | $7.77 M | — | -54.49% | -74.29% | $468.38 / $1.92 | $39.62 |
| 3. | Adaptive Biotechnologies Corporation | $14.58 | — | $2.23 B | — | -13.51% | -27.82% | $20.76 / $6.77 | $1.42 |
| 4. | Syndax Pharmaceuticals, Inc. | $23.78 | — | $2.1 B | — | -66.67% | -1.62% | $25.59 / $8.58 | $0.74 |
| 5. | Moleculin Biotech, Inc. | $2.56 | — | $13.66 M | — | -164.37% | -2.56% | $28.61 / $1.79 | $4.69 |
| 6. | Arcturus Therapeutics Holdings Inc. | $8.9 | — | $251.54 M | — | -32.48% | -28.92% | $24.17 / $5.85 | $7.53 |
| 7. | VivoSim Labs, Inc. | $1.54 | — | $4.02 M | — | -115.61% | -51.07% | $5.3 / $1.25 | $1.7 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.06 M | 0 M | 0 M | 0 M | 0.19 M | — |
| Operating Profit | -19.74 M | -19.2 M | -19.32 M | -14.67 M | -13.31 M | — |
| Net Profit | -13.72 M | -30.62 M | -20.77 M | -13.15 M | -35.34 M | — |
| EPS in Rs | -0.6 | -1.34 | -0.91 | -0.58 | -1.55 | -2.83 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.06 M | 0.44 M | 1.92 M | 18.05 M |
| Operating Profit | -72.92 M | -40.87 M | -23.44 M | -37.44 M |
| Net Profit | -78.26 M | -35.13 M | -31.54 M | -41.66 M |
| EPS in Rs | -3.43 | -1.54 | -1.38 | -1.83 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 116.46 M | 150.73 M | 20.99 M | 33.37 M |
| Total Liabilities | 33.41 M | 17.7 M | 13.69 M | 44.28 M |
| Equity | 83.05 M | 133.03 M | 7.3 M | -10.91 M |
| Current Assets | 105.29 M | 138.89 M | 8.39 M | 16.42 M |
| Current Liabilities | 12.94 M | 6.96 M | 4.62 M | 22.11 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -51.46 M | -49.06 M | -30.68 M | -26.75 M |
| Investing CF | -81.72 M | 0.36 M | -0.13 M | -0.1 M |
| Financing CF | 14.59 M | 175.85 M | 25.04 M | -14.7 M |
| Free CF | -51.46 M | -49.06 M | -30.68 M | -26.85 M |
| Capex | — | — | — | -0.1 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -77.08% | -89.34% | — | — |
| Earnings Growth % | -11.37% | 24.28% | — | — |
| Profit Margin % | -7965.76% | -1639.5% | -230.78% | — |
| Operating Margin % | -9267.8% | -1218.5% | -207.41% | — |
| Gross Margin % | 182.99% | 33.26% | 80.98% | — |
| EBITDA Margin % | -9229.48% | -1210.29% | -206.49% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-12-29 | 1:0.00416667 |
| 2022-07-08 | 1:0.0833333 |